The 2025 Annual General Meeting of Boule Diagnostics AB (publ), ("Boule"), resolved that a Nomination Committee based on the ownership structure on 30 September 2025 shall be appointed to propose the Annual General Meeting 2026:

1. Proposal for Chairman of the Annual General Meeting,
2. Proposal for the Board of Directors,
3. Proposal for Chairman of the Board of Directors,
4. Proposals for fees and other remuneration for Board assignments to each of the Board members and remuneration for committee work,
5. Proposal for auditor,
6. Proposal for fees to the Company's auditor,
7. Proposal for changes to the principles for the appointment of the Nomination Committee and instructions for the Nomination Committee, to the extent deemed necessary, and
8. Other matters that are the responsibility of the Nomination Committee in accordance with the Swedish Corporate Governance Code

Boule's largest shareholders at the time above were AB Grenspecialisten, Svolder AB and Thomas Eklund, representing 36 percent of the share capital and votes. These shareholders have in turn nominated Tomas Risbecker (Svolder AB), Katarina Berggren (AB Grenspecialisten) and Thomas Eklund. The Nomination Committee has subsequently constituted itself and elected Katarina Berggren as its Chairman and co-opted the Chairman of the Board Torben Jörgensen. Shareholders who wish to get in touch with the Nomination Committee are welcome to contact the Chairman of the Nomination Committee Katarina Berggren via e-mail at katarina@grenspecialisten.com. In order for proposals to be able to be evaluated by the Nomination Committee in the required manner, such proposals should have been submitted no later than 1 February 2026.

Contacts
Torben Nielsen, CEO and Group President, torben.nielsen@boule.com, phone +46 (0)70-558 51 05
Holger Lembrér, CFO, holger.lembrer@boule.com, phone +46 (0)72-230 77 10

About Us
Boule Diagnostics AB (publ) is a global company consisting of two business segments, Diagnostics and OEM CDS. Diagnostics is specialized in near-patient, decentralized diagnostic solutions for human and veterinary applications, serving hospitals, clinics, laboratories. OEM CDS develops and delivers reliable reagent, blood controls and calibrators tailored for diagnostic companies worldwide.
With operations in Sweden, the United States, Mexico, and Russia, and a global distribution network spanning more than 100 countries, Boule combines a resilient business model with strong positions in key growth markets. In 2024, Boule reported net sales of SEK 558 million and has about 200 employees worldwide. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com

Attachments
Boule Diagnostics – Nomination Committee for the Annual General Meeting 2026

Läs mer på MFN